These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28150354)

  • 41. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.
    Kulshrestha A; Katara GK; Ginter J; Pamarthy S; Ibrahim SA; Jaiswal MK; Sandulescu C; Periakaruppan R; Dolan J; Gilman-Sachs A; Beaman KD
    Mol Oncol; 2016 Jun; 10(6):789-805. PubMed ID: 26899534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway.
    Zhang Y; Tao L; Fan LX; Huang K; Luo HM; Ge H; Wang X; Wang Q
    Mol Med Rep; 2019 Mar; 19(3):2287-2296. PubMed ID: 30664215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
    Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
    Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 3,6-Dihydroxyflavone regulates microRNA-34a through DNA methylation.
    Peng X; Chang H; Chen J; Zhang Q; Yu X; Mi M
    BMC Cancer; 2017 Sep; 17(1):619. PubMed ID: 28870206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.
    Tu Y; Kim E; Gao Y; Rankin GO; Li B; Chen YC
    Int J Oncol; 2016 Jun; 48(6):2657-65. PubMed ID: 27082635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
    Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
    Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
    Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
    Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
    Sasaki H; Sheng Y; Kotsuji F; Tsang BK
    Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells.
    Cai G; Wang J; Xin X; Ke Z; Luo J
    Int J Oncol; 2007 Sep; 31(3):657-62. PubMed ID: 17671694
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The ubiquitin ligase TRIM56 inhibits ovarian cancer progression by targeting vimentin.
    Zhao L; Zhang P; Su XJ; Zhang B
    J Cell Physiol; 2018 Mar; 233(3):2420-2425. PubMed ID: 28771721
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prolonged wild-type p53 protein accumulation and cisplatin resistance.
    Yazlovitskaya EM; DeHaan RD; Persons DL
    Biochem Biophys Res Commun; 2001 May; 283(4):732-7. PubMed ID: 11350044
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
    Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Platinum sensitivity of ovarian cancer cells does not influence their ability to induce M2-type macrophage polarization.
    Mlynska A; Povilaityte E; Zemleckaite I; Zilionyte K; Strioga M; Krasko J; Dobrovolskiene N; Peng MW; Intaite B; Pasukoniene V
    Am J Reprod Immunol; 2018 Sep; 80(3):e12996. PubMed ID: 29904979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
    Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
    J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
    Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.
    Yao KS; Godwin AK; Johnson SW; Ozols RF; O'Dwyer PJ; Hamilton TC
    Cancer Res; 1995 Oct; 55(19):4367-74. PubMed ID: 7671249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin.
    van Jaarsveld MT; Blijdorp IC; Boersma AW; Pothof J; Mathijssen RH; Verweij J; Wiemer EA
    Eur J Cancer; 2013 Jan; 49(2):345-51. PubMed ID: 23041051
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TET1 inhibits gastric cancer growth and metastasis by PTEN demethylation and re-expression.
    Pei YF; Tao R; Li JF; Su LP; Yu BQ; Wu XY; Yan M; Gu QL; Zhu ZG; Liu BY
    Oncotarget; 2016 May; 7(21):31322-35. PubMed ID: 27121319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.